Endocrinology, Diabetes and Metabolism最新文献

{"title":"Triglyceride-Glucose Index Association With Severity of Coronary Artery Disease","authors":"Sara Saffar Soflaei,&nbsp;Pooria Salehi-Sangani,&nbsp;Zahra Fallahi,&nbsp;Fatemeh Imanparast,&nbsp;Mahdieh Marousi,&nbsp;Mohammad Tajfard,&nbsp;Gordon A. Ferns,&nbsp;Mohsen Moohebati,&nbsp;Majid Ghayour-Mobarhan","doi":"10.1002/edm2.70025","DOIUrl":"https://doi.org/10.1002/edm2.70025","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite previous studies, the relationship between the triglyceride-glucose (TyG) index and coronary artery disease (CAD) is still undetermined. So we aimed to investigate the association between the TyG index and CAD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A total of 2346 subjects were enrolled in the study and were categorised into 5: those with no CAD, angiogram negative (Ang−) patients, those with single-vessel disease (SVD), or two-vessel disease (2VD) or three-vessel disease (3VD). Demographic characteristics, disease history and biochemical investigations were recorded. TyG index was calculated as Ln [fasting TG (mg/dL) × fasting glucose (mg/dL)/2].</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Adjusted regression models demonstrated that the odds of 3VD (OR, 5.847; 95% CI, 4.391–7.784), 2VD (OR, 4.943; 95% CI, 3.597–6.791), SVD (OR, 4.722; 95% CI 3.448–6.647) and a negative coronary angiogram (OR, 3.137; 95% CI, 2.431–4.049), increased significantly per each unit elevation of the TyG index, compared to the healthy participants. Also, the odds for being 3VD (1.864, 95%CI 1.402–2.477, <i>p</i>-value &lt; 0.001), 2VD (1.575, 95%CI 1.143–2.171, <i>p</i>-value = 0.005) and SVD (1.505, 95%CI 1.097–2.065, <i>p</i>-value = 0.011) were increased significantly by one-unit elevation of TyG index, compared to Ang− group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study demonstrates a significant association between elevated TyG index and the presence and severity of CAD. Higher TyG index values were consistently linked to an increased likelihood of multivessel CAD, especially in diabetic patients. These findings suggest that the TyG index could serve as a valuable marker for assessing CAD risk and stratification.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta-Analysis of Randomised Controlled Trials","authors":"Jawad Basit,&nbsp;Mushood Ahmed,&nbsp;Priyansha Singh,&nbsp;Areeba Ahsan,&nbsp;Eeshal Zulfiqar,&nbsp;Javed Iqbal,&nbsp;Maurish Fatima,&nbsp;Prakash Upreti,&nbsp;Mohammad Hamza,&nbsp;M Chadi Alraies","doi":"10.1002/edm2.70039","DOIUrl":"https://doi.org/10.1002/edm2.70039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Inclisiran, a small interfering RNA (siRNA), reduces the levels of low-density lipoproteins (LDL) in the body by preventing the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9). However, there is limited pooled data regarding the efficacy and safety of inclisiran in patients with hypercholesterolemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PubMed/MEDLINE, Embase and the Cochrane Library were searched by investigators from inception till July 2024 to identify randomised controlled trials (RCTs) that investigated inclisiran in patients with hypercholesterolemia. Weighted mean differences (MDs) for continuous outcomes and risk ratios (RRs) for the dichotomous outcomes were pooled. The analysis was conducted using the random effects model, and a <i>p</i>-value of &lt; 0.05 was considered statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 8 RCTs reporting data for 5016 patients were included in the pooled analysis. Our pooled analysis demonstrated that inclisiran was associated with a significant decline in the % of LDL-C levels (MD = −50.42, 95% CI: −56.15 to −44.70), % of PCSK9 levels (MD = −78.57, 95% CI: −81.64 to −75.50), % of total cholesterol levels in the body (MD = −31.22, 95% CI: −33.08.15 to −29.37), and apo B levels (MD = −41.47, 95% CI: −44.83 to −38.11) when compared with the control group. The risk of all-cause death, cardiovascular death, major adverse cardiovascular events, myocardial infarction, stroke, and serious adverse events remained comparable (<i>p</i> &gt; 0.05) across the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Inclisiran reduces LDL-C, PCSK9, cholesterol and apo-B levels in the body without increasing the risk of serious adverse events.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database","authors":"Christophe Abi Zeid Daou,&nbsp;Omar Aboul Hosn,&nbsp;Lana Ghzayel,&nbsp;Marc Mourad","doi":"10.1002/edm2.70038","DOIUrl":"https://doi.org/10.1002/edm2.70038","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>GLP-1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Monjaro), have gained significant popularity for obesity management, but concerns have arisen about their potential link to thyroid cancer. This study investigates the association between thyroid cancer and weight-loss medications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A disproportionality analysis was conducted using data from the FDA Adverse Event Reporting System (FAERS) from 2004 to Q1 2024. Reporting odds ratios (RORs) were used to identify associations between thyroid cancer and weight-loss drugs, including anti-diabetic medications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Significant positive associations with thyroid cancer were found for GLP-1 receptor agonists: semaglutide (ROR = 7.61, 95% CI: 6.37–9.08), dulaglutide (ROR = 3.59, 95% CI: 3.03–4.27), liraglutide (ROR = 15.59, 95% CI: 13.94–17.44) and tirzepatide (ROR = 2.09, 95% CI: 1.51–2.89). A weak inverse association was observed for metformin (ROR = 0.58, 95% CI: 0.36–0.93). No significant associations were found for other drugs, such as topiramate, dapagliflozin and insulin glargine.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study, based on data from the FAERS database, suggests a potential association between GLP-1 receptor agonists and an increased thyroid cancer risk. These findings underscore the importance of further research and continuous safety monitoring when prescribing these medications for obesity management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143571185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Short-Chain Fatty Acids on Glucose, Fatty Acid and Leucine Metabolism in Primary Human Myotubes","authors":"Ragna Husby Tingstad,&nbsp;Oliwia Witczak,&nbsp;Siver Beajani,&nbsp;Seung Hee Seo,&nbsp;Nils Gunnar Løvsletten,&nbsp;Christine Skagen,&nbsp;Mari Charlotte Wik Myhrstad,&nbsp;Vibeke Helen Telle-Hansen,&nbsp;Lars Eide,&nbsp;Arild Christian Rustan,&nbsp;Vigdis Aas","doi":"10.1002/edm2.70042","DOIUrl":"https://doi.org/10.1002/edm2.70042","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Short-chain fatty acids (SCFAs) are small molecule metabolites mainly produced during microbial fermentation of dietary fibre in the gut and have been shown to have a beneficial impact on human health. The aim of this study was to evaluate the effect of SCFAs on human skeletal muscle energy metabolism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Primary human myotubes were analysed for glucose and fatty acid (oleic acid) metabolism, as well as insulin sensitivity and protein synthesis in the presence or absence of SCFAs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The most pronounced effects of SCFAs were observed on ¹⁴C-oleic acid uptake and oxidation, as well as ¹⁴C-leucine uptake and protein synthesis, following butyrate treatment. Butyrate increased ¹⁴C-leucine accumulation twofold, potentially due to protein incorporation. On the other hand, the conversion of ¹⁴C-leucine into free fatty acids was reduced by more than 50% by butyrate. Both ¹⁴C-acetate and ¹⁴C-butyrate were shown to be taken up and utilised by primary human myotubes. None of the SCFAs were found to influence glucose metabolism or insulin effects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The results from the current study thus suggest that among the SCFAs, butyrate emerges as the most powerful SCFA in regulating primary human myotube metabolism.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143564732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Cost and Treatment Effects in the Care Given for Graves' Disease: A Swedish Cost–Utility Analysis","authors":"Lars Lindholm,&nbsp;Gabriel Sjölin,&nbsp;Annika Jonsson,&nbsp;Mirna Abraham-Nordling,&nbsp;Göran Wallin,&nbsp;TT-12 Study Group,&nbsp;Helena Filipsson Nyström","doi":"10.1002/edm2.70034","DOIUrl":"https://doi.org/10.1002/edm2.70034","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Guidelines in healthcare should be evidence-based, satisfy patient needs and improve patient outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a cost–utility analysis in Graves' disease (GD) and estimated incremental costs after the introduction of a national guideline adding the Graves' Recurrent Events After Therapy (GREAT) score with genetic determinants (GREAT+) to predict recurrence, a thyroid nurse, preoperative calcium/vitamin D treatment and thyroid-stimulating immunoglobulins.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>Antithyroid drugs (ATDs) were less costly, achieved 0.88 quality-adjusted life years (QALYs) over 8 years and dominated over radioactive iodine (RAI) treatment. The relevant incremental cost-effectiveness ratio was ATD versus thyroid surgery (Tx). Tx was more costly than ATD but was also more effective. The incremental cost-effectiveness ratio was equal to 40,488 Euro per QALY gained. In recurrent GD, the QALY weight for surgery after ATD was 0.76 compared with 0.79 when surgery was the initial treatment. If individuals requiring surgery could be identified at start of first treatment, QALYs would be higher (6.32) and the cost lower (13,945 Euro). The net cost increase after the new guideline was 17.6%, which was partially an effect from more time being spent with the thyroid nurse. If the GREAT+ score was also applied, the total increased net cost was 14.8% if 24% of the tested patients changed treatment to Tx.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>Tx was more cost-effective than RAI when ablative treatment is advocated. Prediction score for recurrence directing patients to earlier Tx is cost-effective and enables the introduction of a specialist thyroid nurse. Health economic evaluations should accompany future guidelines.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effectiveness of a Primary Care Diabetes Education and Self-Management Program in Ireland: A 6-Month Follow-Up Study","authors":"Clodagh Scannell,&nbsp;Tonya O'Neill,&nbsp;Anne Griffin","doi":"10.1002/edm2.70036","DOIUrl":"https://doi.org/10.1002/edm2.70036","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Self-management education is recognised as an essential element of comprehensive diabetes care. This study aims to assess the impact of the DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed) structured diabetes self-management education programme administered by a registered dietitian in a primary-care setting on key clinical indicators (HbA1c, weight and BMI) in participants who returned for the locally developed 6-month follow-up session.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective analysis was conducted of participants who attended the DESMOND 6-h structured diabetes self-management education programme and returned for the locally developed follow-up programme during 2018 in the Midwest of Ireland. Paired sample t-tests and McNemar chi-square tests were used to assess any differences between baseline and 6 months post-intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 66 participants, mean age of 63 years. At follow-up, HbA1c was reduced by 6.45 mmol/mol (standard deviation (SD): 15.02 mmol/mol, <i>p</i> = 0.006). The number of participants below the 53 mmol/mol cut-off increased from 52% at baseline to 71% at follow-up (<i>p</i> &lt; 0.001). A mean weight reduction of 1.4 kg (SD: 4.4 kg, <i>p</i> = 0.21) was found at follow-up. Those in the overweight BMI category decreased from 30.2% to 26.4%, a clinically significant result.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Better glycaemic control and clinically significant improvements in BMI and weight were seen at 6 months among participants who attended the DESMOND program and returned for the locally developed follow-up session. This supports the emerging evidence of the effectiveness of self-management education for diabetes care. Further research is required to determine the optimal contact time and frequency of sessions required in order to sustain the observed improvement in clinical outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shortened Relative Leukocyte Telomere Length Is Associated With Polycystic Ovary Syndrome and Metabolic Traits","authors":"Raymond N.C. Chan,&nbsp;Chuiguo Huang,&nbsp;Noel Y. H. Ng,&nbsp;Henry C. H. Tam,&nbsp;Claudia H. T. Tam,&nbsp;Feifei Cheng,&nbsp;Kwun Kiu Wong,&nbsp;Mai Shi,&nbsp;Alex C. W. Ng,&nbsp;Atta Y. T. Tsang,&nbsp;Chi Chiu Wang,&nbsp;Lai Ping Cheung,&nbsp;Wing Hung Tam,&nbsp;Mugdha V. Joglekar,&nbsp;Anandwardhan A. Hardikar,&nbsp;Alicia J. Jenkins,&nbsp;Juliana C. N. Chan,&nbsp;Cadmon K. P. Lim,&nbsp;Ronald C. W. Ma","doi":"10.1002/edm2.70030","DOIUrl":"https://doi.org/10.1002/edm2.70030","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Polycystic ovary syndrome (PCOS) is one of the commonest gyneco-endocrine disorders amongst women of reproductive age. Whether PCOS and cardiometabolic traits in PCOS patients are associated with shortened telomere length (TL) or relative leukocyte telomere length (rLTL) remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>214 women with PCOS and 214 age-matched women were recruited. rLTL was measured with an updated quantitative real-time PCR protocol and reported as ΔΔCt between telomere and a single-copy gene encoding β-globin relative to a normalisation control. A two-way Mendelian randomization analysis using the UK Biobank Resource was performed to assess the causal relationship between rLTL and PCOS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Women with PCOS had significantly shortened rLTL (PCOS: 0.5 ± 0.7; control: 0.8 ± 0.6; <i>p</i> &lt; 0.001). Longer rLTL was associated with a lower risk of PCOS after adjusting for age, history of smoking and other cardiometabolic traits (OR: 0.503; 95% CI: 0.342–0.730; <i>p</i> &lt; 0.001). Longer rLTL was associated with reduced risk of dyslidpidemia (OR: 0.563; 95% CI: 0.450–0.968; <i>p</i> = 0.042) in PCOS patients. PCOS subjects with rLTL shorter than mean of the rLTL of control subjects had an elevated risk of dysglycemia (OR: 2.09; 95% CI: 1.04–4.29; <i>p</i> = 0.040). No causal relationships were found between rLTL and PCOS in the Mendelian randomization study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Women with PCOS have significantly reduced rLTL and shorter LTL may be associated with cardiometabolic risk factors in PCOS subjects. There are no causal relationship between genetically determined PCOS and TL or vice versa.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143431682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Serum IL-17A, Renal Function and Diabetic Retinopathy in Type 2 Diabetes Mellitus: Evidence From a Chinese Han Population","authors":"Wensu Wang,&nbsp;Yan Huang,&nbsp;Jianguo Shen,&nbsp;Li Jin,&nbsp;Zhuo Chen","doi":"10.1002/edm2.70033","DOIUrl":"https://doi.org/10.1002/edm2.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Evidence suggested that IL-17A was associated with renal function in type 2 diabetes. We used ultra-sensitive measurement to detect the concentration of IL-17A in human peripheral blood and explored the association of IL-17A with diabetic kidney disease (DKD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We recruited 138 participants from the Shanghai Diabetes Institute Inpatient Database of Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Eighty-four individuals diagnosed as DKD were cases, and 54 type 2 diabetes individuals without DKD or diabetic retinopathy (DR) were controls. The concentration of serum IL-17A was detected by the High Sensitivity Immunoassay Quantitative Kit. Data was analysed by SAS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The concentration of serum IL-17A in our population ranged from 0.07 pg/mL to 2.96 pg/mL with the median of 0.502 pg/mL. Our results suggested that the level of serum IL-17A in DKD case group was higher than in the control (<i>P</i> _{<i>unadjusted</i>} = 0.0496, <i>P</i> _{<i>adjusted</i>} = 0.0298). And serum creatinine, eGFR, ACR were used as indicators of renal function. Serum creatinine and ACR were positive correlated with the level of serum IL-17A (<i>P</i> _{<i>adjusted</i>} = 0.0148; <i>P</i> _{<i>adjusted</i>} = 0.0369), while eGFR showed a negative correlation (<i>P</i> _{<i>adjusted</i>} = 0.0167). Additionally, the level of serum IL-17A was also significantly higher in DR case group compared with the control group (<i>p</i> = 0.0224).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Serum IL-17A level is associated with renal function decline and diabetic retinopathy in patients with type 2 diabetes in a Chinese Han population. Our results suggested that IL-17A may be a potential biomarker of DKD and DR.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between Triglyceride-Glucose Index and Microvascular Complications in Patients With Early- Onset of Type 2 Diabetes Mellitus","authors":"Liu Ran,&nbsp;Yang Han,&nbsp;Hao Zhaohu,&nbsp;Shao Hailin","doi":"10.1002/edm2.70027","DOIUrl":"https://doi.org/10.1002/edm2.70027","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to explore the potential correlation between the triglyceride-glucose (TyG) index and diabetic nephropathy (DN) and diabetic retinopathy (DR) in patients with early-onset type 2 diabetes mellitus (T2DM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>This cross-sectional study statistically analysed TyG index levels across DN and DR stages in patients with early-onset and non-early-onset T2DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients</h3>\u0000 \u0000 <p>A total of 1530 T2DM patients were enrolled between January 2017 and August 2023 at Tianjin Fourth Central Hospital in Tianjin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Measurements</h3>\u0000 \u0000 <p>Correlation analysis and logistic regression were used to examine the association between the TyG index and microvascular complications. Kaplan–Meier plots and Cox regression analyses were employed to evaluate the effects of the TyG index on DN incidence. TyG index's diagnostic ability for DN was explored using the area under the receiver operating characteristic curve.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In patients with early-onset T2DM, the TyG index gradually decreased with DR aggravation and gradually increased with DN aggravation, showing a negative correlation with DR and a positive correlation with DN in patients with early-onset T2DM; logistic regression analysis suggested that the TyG index was an independent risk factor for DN (OR = 1.623, 95% CI = 1.175–2.242). The Cox regression analysis and Kaplan–Meier plots suggested that higher TyG was associated with an earlier incidence of DN in patients with early-onset T2DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In patients with early-onset T2DM, the TyG index could be used to evaluate the risk of microvascular complications, with elevated TyG levels potentially indicating high risk of insulin– resistance related renal injury.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study","authors":"Ahmed Y. Azzam,&nbsp;Muhammed Amir Essibayi,&nbsp;Nathan Farkas,&nbsp;Mohammed A. Azab,&nbsp;Mahmoud M. Morsy,&nbsp;Osman Elamin,&nbsp;Adam Elswedy,&nbsp;Ahmed Saad Al Zomia,&nbsp;Hammam A. Alotaibi,&nbsp;Ahmed Alamoud,&nbsp;Oday Atallah,&nbsp;Hana J. Abukhadijah,&nbsp;Adam A. Dmytriw,&nbsp;Amanda Baker,&nbsp;Deepak Khatri,&nbsp;Neil Haranhalli,&nbsp;David J. Altschul","doi":"10.1002/edm2.70019","DOIUrl":"https://doi.org/10.1002/edm2.70019","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Idiopathic intracranial hypertension (IIH) is a neurological disorder characterised by elevated intracranial pressure (ICP), predominantly affecting obese women of reproductive age. While GLP-1 receptor agonists have shown promise in IIH management, the potential of dual GIP/GLP-1 receptor activation through tirzepatide remains unexplored. This study aimed to evaluate tirzepatide's efficacy as an adjunctive therapy in IIH management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective cohort analysis using the TriNetX Global Health Research Network, analysing data through November 2024. Through propensity score matching, we compared 193 tirzepatide-exposed IIH patients with 193 controls receiving standard care. Primary outcomes included papilledema severity, visual function, headache frequency, and treatment resistance, monitored at multiple follow-up timepoints.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our analysis revealed significant improvements across all measured outcomes in the tirzepatide group. At 24 months, we observed a 68% reduction in papilledema risk (RR 0.320, 95% CI 0.189–0.542, <i>p</i> &lt; 0.001), a 73.9% reduction in visual disturbance and blindness risk (RR 0.261, 95% CI 0.143–0.477, <i>p</i> &lt; 0.001), and a 19.7% reduction in headache risk (RR 0.803, 95% CI 0.668–0.966, <i>p</i> = 0.019). The tirzepatide group demonstrated significant body-mass index reductions, reaching −1.147 kg/m² (95% CI [−1.415, −0.879], <i>p</i> &lt; 0.001) at 24 months compared to controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our results demonstrate that tirzepatide, when used as an adjunctive therapy, provides significant therapeutic benefits in IIH management, particularly in improving papilledema and visual outcomes. Our findings suggest that dual GIP/GLP-1 receptor activation may offer advantages over traditional single-receptor therapies, potentially through enhanced metabolic regulation and direct effects on ICP dynamics.</p>\u0000 </section>\u0000 </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143404413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}